| Topical pimecrolimus: a new horizon for vitiligo treatment? | |
| | |
MedLine Citation:
|
PMID: 17853306 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The purpose of this study was to assess the efficacy of pimecrolimus cream 1% in vitiligo and to evaluate the effects of age of the patients, age of onset and duration of disease on response rate. MATERIALS AND METHODS: Twenty-three patients with vitiligo were enrolled in our study; 19 patients (seven male, 12 female) completed the 6-month study period. Patients were treated with topical pimecrolimus 1% cream once daily. The response was evaluated as excellent (76-100%), moderate (51-75%), mild (26-50%), minimal (1-25%), or no response. RESULTS: The mean age of the 19 patients was 29.3+/-16.6 (range 7-62 years) and the mean duration of vitiligo was 68.4+/-81.3 months. Three patients demonstrated an excellent response to the therapy. Four patients had moderate, six patients had mild and five patients had minimal responses; one patient had no response to the treatment. Side effects were noted as a burning and stinging sensation in only three patients. The correlations between response rate and duration of the disease (r = 0.02, p = 0.95), onset age (r = -0.17, p = 0.48), and age of the patients (r = -0.16, p = 0.53) were not significant. CONCLUSIONS: Pimecrolimus has a mild therapeutic effect on vitiligo without significant side effects and can be an alternative therapy agent. |
| | |
Authors:
|
Neslihan Sendur; Göksun Karaman; Nagehan Saniç; Ekin Savk |
Related Documents
:
|
7473946 - Increased levels of circulating interleukin-8 in patients with large burns: relation to... 425006 - Femoral arteriovenous amino acid differences in septic patients. 21714706 - Clinical and metabolic evaluation of korean patients with urolithiasis. 17727266 - Single breath tracing for carbon dioxide in septic patients with tissue hypoxia. 1378556 - Sister-chromatid exchanges in beta-thalassaemic patients under conditions of in vivo an... 10636446 - Fish analysis of terminal deletions in patients diagnosed with cri-du-chat syndrome. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: The Journal of dermatological treatment Volume: 17 ISSN: 0954-6634 ISO Abbreviation: J Dermatolog Treat Publication Date: 2006 |
Date Detail:
|
Created Date: 2007-09-13 Completed Date: 2007-11-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8918133 Medline TA: J Dermatolog Treat Country: England |
Other Details:
|
Languages: eng Pagination: 338-42 Citation Subset: IM |
Affiliation:
|
Department of Dermatology, Faculty of Medicine, Adnan Menderes University, Aydin, Turkey. neslihansendur@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Cutaneous Adolescent Adult Age Factors Child Dermatologic Agents / administration & dosage* Dosage Forms Female Follow-Up Studies Humans Male Middle Aged Tacrolimus / administration & dosage, analogs & derivatives* Time Factors Treatment Outcome Vitiligo / drug therapy*, pathology |
| Chemical | |
Reg. No./Substance:
|
0/Dermatologic Agents; 0/Dosage Forms; 0/pimecrolimus; 109581-93-3/Tacrolimus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Calcipotriol cream: a review of its use in the management of psoriasis.
Next Document: Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Unde...